-
Gospel to over 30 million patients! Good News on New Drugs for Alzheimer's Disease: Eli Lilly executives have "exposed" drug developments in advance: extreme optimism may become the next hot topic similar to weight loss drugs
On Monday (November 6th) Eastern Time, Dr. Daniel Skovoronsky, the chief scientist of Eli Lilly (NYSE: LLC, stock price $595.19, market value $565 billion), the world's highest pharmaceutical company ... -
Chief Scientific Officer of Lilly: A Major Breakthrough in Alzheimer's Disease is Coming, Like a Weight Loss Drug
Dr. Daniel Skovronsky, Chief Scientific Officer of Lilly, the world's most valuable pharmaceutical company, stated with extreme optimism that a major breakthrough in the treatment of Alzheimer's dise ... -
If Sam Altman returns to his position, Microsoft is considering joining the OpenAI board of directors
On November 20th, The Information reported, citing two sources familiar with the matter, that if dismissed CEO Sam Altman returns to his position, Microsoft will consider taking a seat on the OpenAI ... -
Microsoft CEO Says Former OpenAI CEO Altman Will Join Microsoft
According to Reuters on the 20th, Microsoft CEO Nadella announced on social media that former CEO Sam Altman and former CEO Greg Brockman of the American artificial intelligence research company Open ...- mephistopheles
- 2023-11-20
- サポート
- に反対
- 返信
- コレクション
-
Three twists and turns! Altman's Return to OpenAI Frustrated Will Join Microsoft
According to a report by the Wall Street Journal on the 20th, hopes of Sam Atlman, former CEO of artificial intelligence startup OpenAI, returning to his position have been shattered. On the other ha ... -
Will Altman join Microsoft OpenAI after being dismissed and replicate the Apple of the past
He is the soul of OpenAI, a genius and a madman. If he leaves, this AI company may lose its soul, lose its temperature, and passion. In the eyes of Feng Li, a doctoral supervisor at the School of Com ... -
US FDA Delays Approval of Eli Lilly's New Drug for Alzheimer's Disease
Lilly Pharmaceuticals announced on March 8th local time that the US Food and Drug Administration (FDA) has notified the company to further understand and evaluate the safety and efficacy of its new A ... -
Has the era of AI's iPhone begun? Altman targets AI hardware with a single image to understand his billion dollar investment empire
On April 6th local time, according to technology media The Information, Sam Altman, CEO of OpenAI, and former Apple design director Johnny Avi, a startup founded by OpenAI, announced new financing ne ... -
Has the Expert Committee of the Food and Drug Administration unanimously approved Eli Lilly's new drug? Will Alzheimer's patients have new choices?
On June 10th, Lilly's Alzheimer's disease (AD) drug Donanemab was unanimously approved by the FDA's Advisory Committee on Peripheral and Central Nervous System Drugs (PCNS). -
Eli Lilly's new drug for Alzheimer's disease, Kisumla, has been approved by the US FDA
Lilly's new drug for Alzheimer's disease, Kisunla, has been approved by the US FDA. On July 2nd, Lilly announced that the US Food and Drug Administration (FDA) has approved Kisunla for the treatment ... -
The second Alzheimer's disease drug approved by the United States: Eli Lilly R&D, with an annual treatment cost of $32000
After more than half a year of delay from the initial expected approval time, Lilly's Alzheimer's disease treatment drugs have finally been approved in the United States. On July 2nd local time, Eli ... -
Eli Lilly's new Alzheimer's disease drug Donanemab has been approved for pricing in Japan
On November 13th, the Central Social Insurance Medical Agreement, a consulting agency of the Japanese Ministry of Health, Labour and Welfare, approved the official pricing of the new Alzheimer's dise ...